Peptide Drug Delivery
Explore oral, nasal, transdermal, nanoparticle, and depot injection strategies for delivering peptide therapeutics, including barriers and innovative solutions.
Peptide Drug Delivery
The Peptide Delivery Challenge
Peptide therapeutics face a fundamental paradox: they are exquisitely selective and potent, yet notoriously difficult to deliver. Their peptide bonds are rapidly hydrolyzed by gastrointestinal proteases, their large molecular size limits membrane permeability, and their polarity prevents passive absorption across biological barriers.
Over 80 peptide drugs are currently approved, yet most require injection. Developing effective delivery routes remains one of the most active areas in pharmaceutical research.
Oral Delivery
Oral delivery is the most desired route but the most challenging for peptides.
Barriers:
- Gastric acid (pH 1 to 3) denatures peptides
- Pepsin, trypsin, and chymotrypsin in the GI tract degrade peptide bonds
- The intestinal epithelium presents a physical barrier to large, polar molecules
- First-pass hepatic metabolism further reduces bioavailability
Strategies:
- Permeation enhancers: Compounds like sodium caprate (C10) transiently open tight junctions between epithelial cells
- Enzyme inhibitors: Co-administration of protease inhibitors (such as puromycin or soybean trypsin inhibitor) reduces degradation
- Carrier systems: Nanoparticles and liposomes protect peptides during transit and facilitate uptake
- Chemical modification: Cyclization, D-amino acid substitution, and PEGylation improve stability
Mnemonic: Remember “PEEN” for oral peptide delivery challenges: Proteases, Epithelial barrier, Enzymatic degradation, Narrow absorption window.
Nasal Delivery
The nasal mucosa provides a more permeable route with rich vasculature and avoids first-pass metabolism.
Advantages: Rapid absorption, direct nose-to-brain delivery possible, non-invasive.
Limitations: Mucociliary clearance limits contact time (15 to 20 minutes), variable absorption, limited volume per dose (approximately 100 microliters per nostril).
Examples: Desmopressin (DDAVP) nasal spray for diabetes insipidus, calcitonin nasal spray for osteoporosis.
Transdermal Delivery
The skin offers a large surface area with predictable absorption kinetics, but the stratum corneum presents a formidable barrier.
Strategies:
- Microneedle arrays: Tiny needles (50 to 900 micrometers) create transient pores in the stratum corneum without reaching nerve endings
- Iontophoresis: Electrical current drives charged peptides across the skin
- Chemical enhancers: Compounds like oleic acid and ethanol disrupt lipid packing in the stratum corneum
Nanoparticle Delivery Systems
Nanoparticles encapsulate peptides, protecting them from degradation and enhancing absorption.
Types:
- Polymeric nanoparticles: PLGA (poly lactic-co-glycolic acid) provides sustained release over days to weeks
- Liposomes: Phospholipid bilayers that fuse with cell membranes, releasing peptide cargo intracellularly
- Solid lipid nanoparticles: Lipid matrices that improve stability and permeation
Mnemonic: Remember “PLS” for nanoparticle types: PLGA, Liposomes, Solid lipid nanoparticles.
Depot Injection
Depot formulations provide sustained release from a single injection, improving patient compliance.
Mechanisms:
- Microspheres: PLGA-encapsulated peptides form a depot that releases drug as the polymer degrades (weeks to months)
- Hydrogels: Injectable gels that form in situ, releasing peptide by diffusion
- Implants: Solid rods or pellets placed subcutaneously for months of release
Examples: Leuprolide acetate microspheres (monthly or quarterly injection for prostate cancer), octreotide implants (six-month release for acromegaly).
Comparative Overview
| Route | Bioavailability | Patient Acceptance | Duration |
|---|---|---|---|
| Oral | 1 to 5 percent | High | Acute |
| Nasal | 5 to 20 percent | Moderate | Acute |
| Transdermal | 10 to 30 percent | High | Sustained |
| Injectable depot | 80 to 100 percent | Moderate | Weeks to months |
Key Takeaways
- Oral delivery is most desired but faces enzymatic, physical, and metabolic barriers
- Nasal delivery offers moderate bioavailability with direct CNS access
- Nanoparticle systems protect peptides and enhance absorption through multiple mechanisms
- Depot injections provide sustained release with high bioavailability for chronic conditions